跳至主要内容
临床试验/NCT00417469
NCT00417469已完成3 期

A Single-Blind, Randomized, Single-Center Evaluation of Procedural and Post Procedural Pain Experienced With Injections of NADG With Lidocaine Injectable Gel as Compared to Captique® Injectable Gel in Subjects Undergoing Cutaneous Correction of Nasolabial Folds

Genzyme, a Sanofi Company1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2007年1月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
45
试验地点
1
主要终点
To evaluate the pain experienced during and after the injection procedure for NADGL as compared to Captique® Injectable Gel in subjects undergoing cutaneous correction of nasolabial folds (NLFs).

研究概览

简要总结

The purpose of this research study is to compare subject comfort during and after injection with NADGL and Captique® Injectable Gel, in the nasolabial folds. Captique® is an FDA-approved product without lidocaine and is manufactured by Genzyme Biosurgery (Ridgefield, NJ). NADGL is a new product (not FDA approved) with lidocaine and is also manufactured by Genzyme Biosurgery. We do not know which of these treatments results in less pain during and after injection. The safety of NADGL is also being studied.

详细描述

45 subjects are planned; a portion of these subjects will have skin of color

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •bilateral nasolabial folds with severity score of 3 or 4 on the 6 point scale.

排除标准

  • •pregnant/lactating women
  • •subjects who have an allergy to lidocaine or other amide-type anesthetics

结局指标

主要结局

To evaluate the pain experienced during and after the injection procedure for NADGL as compared to Captique® Injectable Gel in subjects undergoing cutaneous correction of nasolabial folds (NLFs).

次要结局

  • To evaluate the safety of NADGL.

研究者

发起方
Genzyme, a Sanofi Company
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验